Return to University Health's Homepage.

Fred Poordad, MD

UT Health San Antonio
Schedule an appointment: 210-743-4306
Loading...
Loading...

Overview

Practice Locations

Insurance

About

Video

Articles & Publications

Blogs
Specialties
Gastroenterology
Transplant
Areas of Interest/Focus
Hepatology
Board Affiliation/Certification
American Board of Internal Medicine/Gastroenterology
American Board of Internal Medicine/Transplant Hepatology
Education
University of Alberta, 1990
Residency
St Thomas Hospital and Medical Center, 1993
Fellowships
University of South Carolina, 1995
Johns Hopkins Bayview Medical Center - GME, 1996
Languages
English
Gender
Male

University Hospital

4502 Medical Drive
San Antonio,TX 78229
210-358-4000
Location Details
Insurance Accepted
6 Degrees - Transplant
90 Degree Benefits - Commercial
Aetna - Commercial/Exchange (IFP)
Aetna - PPO/EPO/HMO/MC Advantage
Aetna - Smart Care EPO
Aetna - Transplant ONLY
Aetna Better Health - Medicaid-CHIP
Aetna Better Health - Medicaid-STAR
Ancira Enterprises - Direct Employer
Blue Cross Blue Shield of Texas - Exchange (BlueAdvantage)
Blue Cross Blue Shield of Texas - HMO/PPO
Blue Cross Blue Shield of Texas - HPN/EPO (Narrow Network)
Blue Cross Blue Shield of Texas - Medicaid-STAR
Blue Cross Blue Shield of Texas - Medicare Advantage HMO
Blue Cross Blue Shield of Texas - Medicare Advantage PPO
Blue Cross Blue Shield of Texas - Narrow HMO (Blue Essentials)
Blue Cross Blue Shield of Texas - Narrow HMO (Blue Premier)
Blue Cross Blue Shield of Texas - Traditional
Blue Cross Blue Shield of Texas - Transplant Programs
Care Improvement Plus - Medicare Advantage-SNP
Cenpatico - Medicaid-CHIP
Cenpatico - Medicaid-STAR
Cenpatico - Medicaid-STAR Health (Foster Care)
Cenpatico - Medicare Advantage
Community First Health Plans - HMO/Exchange (EPO)
Community First Health Plans - Medicaid-CHIP
Community First Health Plans - Medicaid-CHIP Perinate
Community First Health Plans - Medicaid-STAR
Community First Health Plans - Medicaid-STAR Kids
Community First Health Plans - Medicare Advantage HMO
Coventry - HMO/PPO
Coventry - Work Comp / Auto
Driscoll Health Plan - Medicaid-All
EBSO - TPA
El Paso First - Medicaid-CHIP
El Paso First - Medicaid-STAR
Entrust - TPA
First Health - Commercial PPO
FirstCare (Part of Scott & White Health Plans) - Medicaid-STAR
Gonzaba Medical Group - Transplant ONLY
Healthsmart - Accel
Healthsmart - Commercial PPO
Healthsmart - HPO/POS
Humana - Commercial Behavioral Health
Humana - Exchange (HMOx)
Humana - HMO/PPO/Behavioral Health
Humana - Medicare Advantage Behavioral Health
Humana - Medicare Advantage HMO (Gold)
Humana - Medicare Advantage PPO
Humana - National Transplant ONLY Network
Humana Military - TRICARE
Imperial Health Plan - Medicare Advantage
Independent Medical Systems (IMS) - PPO
Interlink - Transplant
LifeTrac - Transplant
Magellan - Commercial and Medicaid Behavioral Health
Molina - Commercial Exchange
Molina - Medicaid-CHIP
Molina - Medicaid-CHIP Perinate
Molina - Medicaid-STAR
Molina - Medicare Advantage
Molina - Medicare-Medicaid Duals
MultiPlan - Work Comp
MultiPlan - Wrap Network
OptumHealth - Transplant ONLY
Oscar - Commercial Exchange
Point Comfort Underwriters (PCU) - Refugee Medical Assistance
Point Comfort Underwriters (PCU) - Unaccompanied Children
Prime Health Services - Commercial PPO
Prime Health Services - Medicare Advantage
Private Healthcare Systems (PHCS) - Commercial PPO
ProCare Advantage - Medicare Advantage I-SNP
Provider Network of America (PNOA) - Commercial
Provider Partners Health Plan (PPHP) - Medicare Advantage I-SNP
Scott & White Health Plan - HMO/PPO/Medicare Advantage
Superior HealthPlan - Medicaid-CHIP
Superior HealthPlan - Medicaid-CHIP Perinate
Superior HealthPlan - Medicaid-STAR
Superior HealthPlan - Medicaid-STAR Health (Foster Care)
Superior HealthPlan - Medicaid-STAR Kids
Superior HealthPlan - Medicaid-STAR PLUS
Superior HealthPlan - Medicare Advantage (Allwell)
Superior HealthPlan - Medicare-Medicaid Duals (Allwell)
Texas Independence Health Plan - Medicare Advantage I-SNP
Three Rivers Provider Network - PPO
Tokio Marine - Transplant
TriWest (via BCBSTX) - VA CCN Program
UnitedHealthcare - Medicaid-STAR
UnitedHealthcare - Medicaid-STAR Kids
UnitedHealthcare - Medicaid-STAR PLUS
UnitedHealthcare - Medicare Advantage
UnitedHealthcare - PPO
Universal Benefits Consortium - Brokerage Firm (School Districts)
University of Incarnate Word (Gilsbar) - Direct Employer
Velocity National Provider Network - Commercial PPO
Velocity National Provider Network - Wrap Network
WellCare - Medicare Advantage
WellMed - Medicare Advantage
WellPoint (Gonzaba) - Medicare Advantage (TRANSPLANTS ONLY)
WellPoint - Medicaid-CHIP
WellPoint - Medicaid-CHIP Perinate
WellPoint - Medicaid-STAR
WellPoint - Medicaid-STAR Kids
WellPoint - Medicaid-STAR PLUS
WellPoint - Medicare Advantage
WellPoint - Medicare-Medicaid Duals
Please contact your health insurance company to confirm provider participation. For billing and insurance questions, please call our Billing Department at 210-358-3260.
I am Vice President of Academic and Clinical Affairs at the Texas Liver Institute. I served as the co-director of liver transplantation at Johns Hopkins prior to becoming the chief of hepatology and liver transplantation at Cedars-Sinai Medical Center in Los Angeles, where I served for 10 years.
I also serve as a Clinical Professor of Medicine at UT Health San Antonio and as Chief of the Division of Hepatology at the Liver Transplant Center.
I sit on national committees for the American Association for the Study of Liver Diseases (AASLD) and American College of Gastroenterology (ACG), and have authored over 300 papers and book chapters. I am internationally recognized for my work in liver disease research and teaching.
In addition, I created an accredited transplant hepatology fellowship program at UT Health San Antonio, and serve as program director. I teach medical students, resident and fellows, and rotate on the liver transplant service.
Since 2015, I have served on the Executive Committee for the Mays Cancer Center in San Antonio. I attend inpatient and outpatient services at UT Health San Antonio.

Book Chapters

  1. Reau N, Poordad F. Primary Liver Cancer, Hepatocellular Carcinoma. Edited by Reau N and Poordad F. 2012 Humana Press.
  2. Poordad FF. Clinics in Liver Disease, A New Era in Hepatitis C. Edited by Poordad, F. 2011.
  3. Chee GM, Poordad FF. Hbv therapy following unsuccessful interferon therapy: how do you see the role for oral therapies? Clinical Dilemmas in Viral Liver Disease, 1st Edition, 2010, Blackwell Publishing.
  4. Poordad F, Chee GM. Pharmacology and mechanisms of action of antiviral drugs: Ribavirin analogues. Advanced Therapy for Hepatitis C Infection. 2010, Wiley-Blackwell.
  5. Poordad FF. Chronic Hepatitis C Infection: Factors Promoting Progression of Disease. Schiff’s Diseases of The Liver, 9th Edition.
  6. Poordad FF. Evaluation of Abnormal Liver Enzymes and the Role of Liver Biopsy. Advanced Therapy of Gastroenterology and Liver Disease, 5th Edition.; 604-610.

Other Publications

  1. Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, Coste A, Poordad F, Karsdal M, Nielson M, Goodman Z, Charles ED. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 2022 Apr; 75(4): 912-923. doi: 10.1002/hep.32181. Epub 2021 Dec 13.
  2. Flamm SL, Brown K, Wadei HM, Brown RS Jr, Kugelmas M, Samaniego-Picota M, Burra P, Poordad F, Saab S. The current management of hepatorenal syndrome-acute kidney injury in the United States and the potential of terlipressin. Liver Transpl. 2021 Aug; 27(8): 1191-1202. doi: 10.1002/lt.26072.
  3. Wiles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L Jr, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019 May;70(5): 1019-1023.
  4. Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 Jan 25;378(4):354-369.
  5. Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C, Gutierrez J. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV. Hepatology. 2017 Feb 21. doi: 10.1002/hep.29130.
  6. Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017 Feb 3;5(4):371-375.
  7. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment. Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081. [Epub ahead of print].
  8. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 Apr 13. pii: S0168-8278(17)30211-8. doi: 10.1016/j.jhep.2017.03.039. [Epub ahead of print].
  9. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial. Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541. [Epub ahead of print].
  10. Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa F. Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671. [Epub ahead of print].
  11. Poordad F, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E, Mobashery N, Tatsch F, Foster GR. Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis. J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083-4. doi: 10.1016/j.jhep.2017.06.011. [Epub ahead of print].
  12. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence. Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446. [Epub ahead of print].
  13. Poordad F. Diagnosis, Treatment, and Monitoring of Patients With Primary Biliary Cholangitis. Gastroenterol Hepatol (N Y). 2016 Sep;12(9):561-564.
  14. Poordad F, Landis CS, Asatryan A, Jackson DF, Ng TI, Fu B, Lin CW, Yao B, Kort J. High Antiviral Activity of NS5A Inhibitor ABT-530 With Paritaprevir/Ritonavir and Ribavirin Against Hepatitis C Virus Genotype 3 Infection. Liver Int. 2016 Jan 18. doi: 10.1111/liv.13067. [Epub ahead of print].
  15. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 in Patients with HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016. pii: S0016-5085(16)34816-8.
  16. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313(17):1736-44.
  17. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lee S, Gane EJ. Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients with Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA. Gastroenterology. 2015;148(1):263.
  18. Poordad F. Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician. Clin Liver Dis. 2015;19(4):ix-x.
  19. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low Relapse Rate Leads to High Concordance of SVR12 with SVR24 After Treatment with ABT-450/r, Ombitasvir, Dasabuvir Plus Ribavirin in Subjects with Chronic HCV Genotype 1 Infection in the AVIATOR Study. Clin Infect Dis. Clin Infect Dis. 2015;60(4):608-10.
  20. Forns X, Poordad F, Pedrosa M, Berenguer M, Wedemeyer H, Ferenci P, Shiffman ML, Fried MW, Lovell S, Trinh R, Lopez-Talavera JC, Everson G. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminemia. Liver Int. 2015;35(11):2358-62.
  21. Poordad FF. Presentation and complications associated with cirrhosis of the liver. Curr Med Res Opin. 2015:1-27.
  22. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61(3):769-75.
  23. Poordad F, Rustgi V, Brown RS Jr, Patel V, Kugelmas M, Regenstein F, Balart L, LaBrecque D, Brown K, Avila M, Biederman M, Freed G, Smith R, Bernstein M, Arnold H, Cahan J, Fink S, Katkov W, Massoumi H, Harrison S. The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). Therap Adv Gastroenterol. 2015;8(5):263-9.
  24. Poordad F. Treatment of Hepatitis C Virus Genotype 3 Infection. Gastroenterol Hepatol (N Y). 2015;11(10):715-7.
  25. Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD. UNITY-1 Study Group. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015;313(17):1728-35.
  26. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Silva-Tillmann BD, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med. 2014;370(21):1973-82.
  27. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222-32.
  28. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, Dasilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 2014;370(17):1604-14.
  29. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414-26.
  30. Lawitz E, Poordad FF, Pang P, Hyland R, Ding X, Mo H, Symonds W, McHutchison J, Membreno F. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomized, phase 2 trial. Lancet. 2014;383(9916):515-23.
  31. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Reddy KR, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir. Analysis from the SPRINT-2 trial. Hepatology. 2013;57(3):974-84.
  32. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson D, Rossaro L, Balart L, Morgan T, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial. Gastroenterology 2013;145(5):1035-1044.
  33. Poordad F, Lawitz E, Kowdley K, Cohen D, Podsacki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. N Engl J Med 2013;368:45-53.
  34. Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein A. Phase 2a Trial of 12-Week Interferon-Free Therapy with Two Direct-Acting Antivirals (ABT-450/r, ABT-072) and Ribavirin in IL28B C/C Patients with Chronic Hepatitis C Genotype 1. J Hepatol. 2013;59(1):18-23.
  35. 6. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143(3):608-618.
  36. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR. SPRINT-2 and RESPOND-2 Investigators. Gastroenterology. 2012;143(3):608-618.
  37. Poordad F; McCone J; Bacon B; Bruno S; Manns M; Sulkowski M; Jacobson I; Reddy R; Boparai N; Sniukien V; Brass C; Albrecht JK. Bronowicki JP for the Sprint 2 Investigators. Boceprevir with Peginterferon and Ribavirin for Chronic Hepatitis C. N Engl J Med. 2011;364:1195-1206.
  38. Poordad F, Theodore D, Sullivan J, Grotzinger K. Medical Resource Utilization and Healthcare Costs in Patients with Chronic Hepatitis C Viral Infection and Thrombocytopenia. J Med Econ. 2011;14(2):194-206.
  39. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11): 1014-24.
  40. Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54(5):1538-46.
  41. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP . Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-81..
  42. Poordad F, Lawitz E, Shiffman ML, Hassanein T, Muir AJ, Bacon BR, Heise J, Halliman D, Chun E, Hammond J. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2010;52(4):1208-15.
  43. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, Dasilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 2014;370(17):1604-14.
New hope for hepatitis C patients
December 11, 2019
Call 210-743-4306 to request an appointment with this doctor.
Back to Search
Patient reviews

    Download Our Mobile App

    Access health information, get turn-by-turn navigation in University Hospital, find a doctor or location, and more.
    Learn more